<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content

Prostate Radiopharmacology In Vivo Screen

Champions’ latest in vivo screen integrates advanced radiochemistry with prostate PDX models, enabling translational evaluation of radiopharmaceuticals in clinically relevant systems.

Now Enrolling until August 29th, 2025

 

 

11 Prostate PDX Models with Diverse PSMA Expression Now Available

This screen includes 11 clinically annotated prostate cancer PDX models, spanning the full range of PSMA IHC scores, metastatic sites, and prior treatments. All models are available for immediate in vivo screening.

New model highlights include:

Use this screen to:

  • Tumors harvested from bone, lymph node, liver, and prostate sites
  • Prior therapies including enzalutamide, leuprolide, and olaparib
  • Detailed annotation with histology, tumor grade, treatment history, and metastatic status
  • PSMA expression confirmed by IHC
  • Benchmark novel PSMA-targeting agents
  • Validate biodistribution in high- and low-expression models
  • Generate data that supports INDs and future clinical trial planning
  • Reduce development costs through shared control arms

Integrated Radiochemistry & Clinically Relevant Models

Champions is the only preclinical CRO offering both radiochemistry and clinically relevant prostate PDX models under one roof—enabling true end-to-end workflows.

 Full Lifecycle Support

In-house radiolabeling, biodistribution, and efficacy studies

Access to Scarce Isotopes

Access to a variety of isotopes including but not limited to Ac225, Lu-177

Flexible Endpoints

Endpoints available upon request: biodistribution, IHC, flow cytometry, tumor harvests (FFPE, snap frozen)

Target Validation

Optional terminal tumor collections for target validation

Molecular & Phenotypic Characterization

All 11 models feature detailed profiling across key translational biomarkers and clinical attributes:

  • PSMA IHC expression
  • Includes models with pretreatment resistance history to targeted treatments and the latest immunotherapies, such as lenalidomide and tafasitamab-cxix antibody therapy targeting CD19.
  • Multi-omic data: HLA typing, MSI/LST scores, and readily available slides for additional IHC markers  evaluation
  • Several endpoint data options available including Flow Cytometry and IHC to quantify target expression and critical phenotypical changes (available upon request).